NKTR-358: A novel regulatory T-cell stimulator that selectively stimulates expansion and suppressive function of regulatory T cells for the treatment of autoimmune and inflammatory diseases
Neha Dixit(Nektar Therapeutics (United States)), Jonathan Zalevsky(Nektar Therapeutics (United States)), Vidula Dixit(Nektar Therapeutics (United States)), Laurie A. VanderVeen(Gilead Sciences (United States)), Peiwen Kuo(Nektar Therapeutics (United States)), Mekhala Maiti(Nektar Therapeutics (United States)), Myong Lee(Nektar Therapeutics (United States)), Yusuke Kamihara(Sapporo Medical University), Janet Cetz(Nektar Therapeutics (United States)), Chunmei Ji(Bengbu Medical College), Thomas K. H. Chang(University of British Columbia), Yolanda Kirksey(Princeton University), Stephen K. Doberstein(Xencor (United States)), Christie Fanton(Nektar Therapeutics (United States)), Grace Kim(University of California, San Francisco), Ping Zhang(Ningbo University), Yinyan Tang(Merck & Co., Inc., Rahway, NJ, USA (United States)), Peter Kirk(Immunocore (United Kingdom)), Theresa D. Sweeney(Nektar Therapeutics (United States)), Werner Rubas(University of California, San Francisco), John L. Langowski(Novartis (Switzerland)), Jerome Ritz(Dana-Farber Cancer Institute)
Cited by 54
Related Papers
Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial
|Nature|2018|1.5k
Interleukin-2 and Regulatory T Cells in Graft-versus-Host Disease
|New England Journal of Medicine|2011|1.1k
β-Arrestin–Dependent Endocytosis of Proteinase-Activated Receptor 2 Is Required for Intracellular Targeting of Activated Erk1/2
|The Journal of Cell Biology|2000|816
Enhanced antibody half-life improves in vivo activity
|Nature Biotechnology|2010|654